Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 985.17%.

  • Protagonist Therapeutics' EBITDA Margin fell 984700.0% to 985.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.34%, marking a year-over-year decrease of 381800.0%. This contributed to the annual value of 58.2% for FY2024, which is 2142900.0% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' EBITDA Margin is 985.17%, which was down 984700.0% from 758.04% recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' EBITDA Margin ranged from a high of 80.92% in Q1 2024 and a low of 4604.78% during Q2 2022
  • For the 5-year period, Protagonist Therapeutics' EBITDA Margin averaged around 710.36%, with its median value being 388.12% (2021).
  • Per our database at Business Quant, Protagonist Therapeutics' EBITDA Margin tumbled by -100797100bps in 2021 and then surged by 3971100bps in 2022.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' EBITDA Margin stood at 429.57% in 2021, then surged by 92bps to 32.46% in 2022, then soared by 242bps to 46.1% in 2023, then soared by 67bps to 76.84% in 2024, then tumbled by -1382bps to 985.17% in 2025.
  • Its EBITDA Margin stands at 985.17% for Q3 2025, versus 758.04% for Q2 2025 and 68.18% for Q1 2025.